EDINBURGH, Scotland, Jan. 15, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the precli ...

EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO Bryan Kobel will be presenting a corporate overview at the upcoming Sequire Investor Summit 2025. The conference is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more informati ...

EDINBURGH, Scotland, Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository Shares (ADSs) has continued trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol 'TCBP'. There has been no halt in trading and shares are expected to continue trading unabated. This pres ...

EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special ...

EDINBURGH, Scotland, Dec. 20, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adverse Events seen in any of the restart patients. The ACHIEVE UK clinical trial is an open-label, phase II study designed ...

EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting ...

On Wednesday, TC BioPharm (Holdings) PLC TCBP announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval.The company intends to hold a general meeting of shareholders on Monday, December 30.The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the company's stock at the close of trading on January 02, 2025."We are extremely pleased to announce this special ...

Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025EDINBURGH, Scotland, Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced an update on the progression of the ACHIEVE UK Trial.As of this week, over hal ...

Exhibit 99.1 Unless we state otherwise or the context otherwise requires, the terms "TC Biopharm,", "TCB", "we," "us," "our" and the "Company" refer to TC Biopharm (Holdings) plc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than ...

文章核心观点 - TC BioPharm获得G-Rex® Grant Program的25万美元非稀释性资金，用于支持TCB008制造过程的优化，预计将在2025年上半年实现产量增加和成本降低的目标 [1][3][4] G-Rex® Grant Program - G-Rex® Grant Program是由ScaleReady与Wilson Wolf Manufacturing和BioTechne Corporation共同发起的2000万美元计划，旨在推动细胞和基因修饰细胞疗法（CGT）的开发和制造 [2] - 该计划还为受助者提供ScaleReady不断扩大的G-Rex® Grant Partners联盟的独家支持，这些合作伙伴提供cGMP合规制造、质量、监管事务、业务运营等方面的最佳工具和技术 [2] TCB008制造过程优化 - 25万美元的资助将支持TCB008制造过程在未来18个月内的优化，由Dr. Lauren Bor及其团队负责 [3] - 公司计划通过优化过程，在2024年宣布的目标基础上，进一步增加产量并降低成本，目标是在大规模生产中增加产量并降低成本超过80% [4] - 预计这些优化将在2025年上半年实现，比原计划提前12个月 [4] 公司和行业展望 - TC BioPharm是开发γδ T细胞疗法的领导者，并首次在肿瘤学领域进行II/关键临床研究 [7][8] - 公司正在进行两个由研究者发起的临床试验，包括一个针对急性髓系白血病的IIb/III期关键试验，使用公司专有的同种异体CryoTC技术为全球诊所提供冷冻产品 [8] - 该资助将加速TCB008的生产规模扩大，降低成本，使其成为所有患者都能负担得起的细胞疗法选项 [4]